ストックスクリーナーアプリを入手
9.475
1.54%
-0.145
Karyopharm Therapeutics Inc (KPTI) 最新ニュース
KPTIKaryopharm Therapeutics Inc Latest SEC Filings - Finviz
KPTI News | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Karyopharm gives 4 new hires stock awards vesting over 3 years - Stock Titan
Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Index - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Value Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 2000 Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 3000E Index - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) added to Russell 3000E Growth Benchmark - marketscreener.com
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) added to Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Price to sales forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Price to earnings forward of Karyopharm Therapeutics Inc. – NASDAQ:KPTI - TradingView
Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis $KPTI - MarketBeat
Karyopharm Therapeutics, Inc. Actuals & Estimates (NASDAQ:KPTI) - TradingView
25K0 Forecast — Price Target — Prediction for 2027 - TradingView
KPTI Forecast — Price Target — Prediction for 2027 - TradingView
Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dyne Therapeutics Appoints Barry Greene to Board of Directors - GlobeNewswire
Karyopharm Therapeutics Inc (KPTI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell - Seeking Alpha
Karyopharm Therapeutics Inc (KPTI) Valuation: PE, PB & Fair Value Analysis - TradingKey
H.C. Wainwright reiterates Karyopharm stock rating on trial data By Investing.com - Investing.com Canada
Karyopharm Therapeutics Inc (KPTI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Karyopharm Therapeutics Inc (KPTI) Institutional Confidence - TradingKey
H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Karyopharm Therapeutics Inc (KPTI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Karyopharm Therapeutics Inc (KPTI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Karyopharm Therapeutics Inc (KPTI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Karyopharm Therapeutics Inc (KPTI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Karyopharm Therapeutics presents new Phase 3 SENTRY trial data in myelofibrosis at EHA - Traders Union
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - TradingView
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - GlobeNewswire Inc.
Karyopharm Therapeutics secures EHA Congress acclaim for late-breaking SENTRY trial update - Traders Union
Cantor Fitzgerald reiterates Overweight on Karyopharm stock - Investing.com UK
Cantor Fitzgerald reiterates Overweight on Karyopharm stock By Investing.com - Investing.com South Africa
How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI) - Yahoo Finance
T. Rowe Price (KPTI) files Schedule 13G/A showing 6.6% position - Stock Titan
KPTI: Phase III data in myelofibrosis and endometrial cancer signal major advances and rapid adoption - TradingView
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 - Karyopharm
Cancer expert joins Karyopharm's June 8 investor webcast - Stock Titan
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-06-02 - Seeking Alpha
KPTI: Karyopharm's Abstract Accepted for Presentation at Europea - GuruFocus
KPTI: Karyopharm Announces Positive Phase 3 SENTRY Trial Results - GuruFocus
KPTI: Selinexor plus ruxolitinib nearly doubled spleen response and improved survival in myelofibrosis - TradingView
Karyopharm reports phase 3 myelofibrosis trial results at ASCO - Investing.com UK
Karyopharm reports phase 3 myelofibrosis trial results at ASCO By Investing.com - Investing.com Nigeria
Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis - marketscreener.com
Karyopharm’s myelofibrosis trial selected for EHA presentation By Investing.com - Investing.com South Africa
Karyopharm’s myelofibrosis trial selected for EHA presentation - Investing.com UK
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 - Karyopharm
Cancer trial suggests spleen shrinkage may predict survival in myelofibrosis - Stock Titan
1.16%
0.48%
大文字化:
|
ボリューム (24 時間):